 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or [0m
[34mdecrease the risk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of mortality after myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes METOPROLOL TARTRATE increase or [0m
[32mdecrease the risk of mortality after myocardial infarction?[0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes METOPROLOL TARTRATE increase or decrease the risk of mortality after myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"METOPROLOL TARTRATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: METOPROLOL TARTRATE: indications_and_usage: INDICATIONS AND USAGE Hypertension Metoprolol tartrate tablets, USP are indicated for the treatment of hypertension. They may be used alone or in [0m
[31mcombination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets, USP are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate [0m
[31mtablets, USP are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality when used alone or in [0m
[31mconjunction with intravenous metoprolol. Oral metoprolol tartrate tablets, USP therapy can be initiated after intravenous metoprolol therapy or, alternatively, oral treatment can begin within [0m[1;31m3[0m[31m to [0m[1;31m10[0m[31m [0m
[31mdays of the acute event [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: warnings: WARNINGS Heart Failure Beta blockers, like metoprolol, can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock.[0m
[31mIf signs or symptoms of heart failure develop, treat the patient according to recommended guidelines. It may be necessary to lower the dose of metoprolol or to discontinue it. Ischemic Heart Disease [0m
[31mDo not abruptly discontinue metoprolol therapy in patients with coronary artery disease. Severe exacerbation of angina, myocardial infarction and ventricular arrhythmias have been reported in patients[0m
[31mwith coronary artery disease following the abrupt discontinuation of therapy with beta-blockers. When discontinuing chronically administered metoprolol, particularly in patients with coronary artery [0m
[31mdisease, the dosage should be gradually reduced over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks and the patient should be carefully monitored. METOPROLOL TARTRATE: warnings: If angina markedly worsens or acute coronary[0m
[31minsufficiency develops, metoprolol administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients [0m
[31mshould be warned against interruption or discontinuation of therapy without the physicianâ€™s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to [0m
[31mdiscontinue metoprolol therapy abruptly even in patients treated only for hypertension. Use During Major Surgery Chronically administered beta-blocking therapy should not be routinely withdrawn prior [0m
[31mto major surgery; however, the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. Bradycardia Bradycardia, [0m
[31mincluding sinus pause, heart block, and cardiac arrest have occurred with the use of metoprolol. Patients with first-degree atrioventricular block, sinus node dysfunction, or conduction disorders may [0m
[31mbe at increased risk. METOPROLOL TARTRATE: warnings: Monitor heart rate and rhythm in patients receiving metoprolol. If severe bradycardia develops, reduce or stop metoprolol. Exacerbation of [0m
[31mBronchospastic Disease Patients with bronchospastic disease, should, in general, not receive beta blockers, including metoprolol. Because of its relative beta [0m[1;31m1[0m[31m selectivity, however, metoprolol may be[0m
[31mused in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Because beta [0m[1;31m1[0m[31m selectivity is not absolute use the lowest possible dose of [0m
[31mmetoprolol and consider administering metoprolol in smaller doses three times daily, instead of larger doses two times daily, to avoid the higher plasma levels associated with the longer dosing [0m
[31minterval [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m. Bronchodilators, including beta [0m[1;31m2[0m[31m agonists, should be readily available or administered concomitantly.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pharmacokinetics: Renal Impairment The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree [0m
[31mfrom those in normal subjects. Hepatic Impairment Since the drug is primarily eliminated by hepatic metabolism, hepatic impairment may impact the pharmacokinetics of metoprolol. The elimination [0m
[31mhalf-life of metoprolol is considerably prolonged, depending on severity [0m[1;31m([0m[31mup to [0m[1;31m7.2[0m[31m h[0m[1;31m)[0m[31m. Clinical Studies Hypertension In controlled clinical studies, metoprolol has been shown to be an effective [0m
[31mantihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics, at dosages of [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg daily. METOPROLOL TARTRATE: pharmacokinetics: In controlled, comparative, [0m
[31mclinical studies, metoprolol has been shown to be as effective an antihypertensive agent as propranolol, methyldopa, and thiazide-type diuretics, to be equally effective in supine and standing [0m
[31mpositions. Angina Pectoris In controlled clinical trials, metoprolol, administered two or four times daily, has been shown to be an effective antianginal agent, reducing the number of angina attacks [0m
[31mand increasing exercise tolerance. The dosage used in these studies ranged from [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg daily. A controlled, comparative, clinical trial showed that metoprolol was indistinguishable from [0m
[31mpropranolol in the treatment of angina pectoris. METOPROLOL TARTRATE: pharmacokinetics: Myocardial Infarction In a large [0m[1;31m([0m[1;31m1[0m[31m,[0m[1;31m395[0m[31m patients randomized[0m[1;31m)[0m[31m, double-blind, placebo-controlled clinical study, [0m
[31mmetoprolol was shown to reduce [0m[1;31m3[0m[31m-month mortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction. Patients were randomized and treated as soon as possible after their arrival in [0m
[31mthe hospital, once their clinical condition had stabilized and their hemodynamic status had been carefully evaluated. Subjects were ineligible if they had hypotension, bradycardia, peripheral signs of[0m
[31mshock, and/or more than minimal basal rales as signs of congestive heart failure. Initial treatment consisted of intravenous followed by oral administration of metoprolol or placebo, given in a [0m
[31mcoronary care or comparable unit. Oral maintenance therapy with metoprolol or placebo was then continued for [0m[1;31m3[0m[31m months. After this double-blind period, all patients were given metoprolol and followed [0m
[31mup to [0m[1;31m1[0m[31m year. METOPROLOL TARTRATE: pharmacokinetics: The median delay from the onset of symptoms to the initiation of therapy was [0m[1;31m8[0m[31m hours in both the metoprolol- and placebo-treatment groups. Among [0m
[31mpatients treated with metoprolol, there were comparable reductions in [0m[1;31m3[0m[31m-month mortality for those treated early [0m[1;31m([0m[31mâ‰¤[0m[1;31m8[0m[31m hours[0m[1;31m)[0m[31m and those in whom treatment was started later. Significant reductions in the [0m
[31mincidence of ventricular fibrillation and in chest pain following initial intravenous therapy were also observed with metoprolol and were independent of the interval between onset of symptoms and [0m
[31minitiation of therapy. In this study, patients treated with metoprolol received the drug both very early [0m[1;31m([0m[31mintra-venously[0m[1;31m)[0m[31m and during a subsequent [0m[1;31m3[0m[31m-month period, while placebo patients received no [0m
[31mbeta-blocker treatment for this period. The study thus was able to show a benefit from the overall metoprolol regimen but cannot separate the benefit of very early intravenous treatment from the [0m
[31mbenefit of later beta-blocker therapy. METOPROLOL TARTRATE: pharmacokinetics: Nonetheless, because the overall regimen showed a clear beneficial effect on survival without evidence of an early adverse[0m
[31meffect on survival, one acceptable dosage regimen is the precise regimen used in the trial. Because the specific benefit of very early treatment remains to be defined however, it is also reasonable to[0m
[31madminister the drug orally to patients at a later time as is recommended for certain other beta-blockers.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: dosage_and_administration: DOSAGE AND ADMINISTRATION Hypertension Individualized the dosage of metoprolol tartrate tablets. Metoprolol tartrate tablets should be taken [0m
[31mwith or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily in single or divided doses, whether used alone or added to a diuretic. Increase the dosage [0m
[31mat weekly [0m[1;31m([0m[31mor longer[0m[1;31m)[0m[31m intervals until optimum blood pressure reduction is achieved. In general, the maximum effect of any given dosage level will be apparent after [0m[1;31m1[0m[31m week of therapy. The effective [0m
[31mdosage range of metoprolol tartrate tablets is [0m[1;31m100[0m[31m to [0m[1;31m450[0m[31m mg per day. Dosages above [0m[1;31m450[0m[31m mg per day have not been studied. METOPROLOL TARTRATE: dosage_and_administration: While once-daily dosing is [0m
[31meffective and can maintain a reduction in blood pressure throughout the day, lower doses [0m[1;31m([0m[31mespecially [0m[1;31m100[0m[31m mg[0m[1;31m)[0m[31m may not maintain a full effect at the end of the [0m[1;31m24[0m[31m-hour period, and larger or more [0m
[31mfrequent daily doses may be required. This can be evaluated by measuring blood pressure near the end of the dosing interval to determine whether satisfactory control is being maintained throughout the[0m
[31mday. Beta [0m[1;31m1[0m[31m selectivity diminishes as the dose of metoprolol is increased. Angina Pectoris The dosage of metoprolol tartrate tablets should be individualized. Metoprolol tartrate tablets should be [0m
[31mtaken with or immediately following meals. The usual initial dosage of metoprolol tartrate tablets is [0m[1;31m100[0m[31m mg daily, given in two divided doses. Gradually increase the dosage at weekly intervals until [0m
[31moptimum clinical response has been obtained or there is pronounced slowing of the heart rate. METOPROLOL TARTRATE: dosage_and_administration: The effective dosage range of metoprolol tartrate tablets [0m
[31mis [0m[1;31m100[0m[31m to [0m[1;31m400[0m[31m mg per day. Dosages above [0m[1;31m400[0m[31m mg per day have not been studied. If treatment is to be discontinued, gradually decrease the dosage over a period of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m weeks [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. [0m
[31mMyocardial Infarction Early Treatment During the early phase of definite or suspected acute myocardial infarction, initiate treatment with metoprolol tartrate tablets as soon as possible after the [0m
[31mpatient's arrival in the hospital. Such treatment should be initiated in a coronary care or similar unit immediately after the patientâ€™s hemodynamic condition has stabilized. Begin treatment in this [0m
[31mearly phase with the intravenous administration of three bolus injections of [0m[1;31m5[0m[31m mg of metoprolol tartrate each; give the injections at approximately [0m[1;31m2[0m[31m-minute intervals. During the intravenous [0m
[31madministration of metoprolol, monitor blood pressure, heart rate, and electrocardiogram. METOPROLOL TARTRATE: dosage_and_administration: In patients who tolerate the full intravenous dose [0m[1;31m([0m[1;31m15[0m[31m mg[0m[1;31m)[0m[31m, [0m
[31minitiate metoprolol tartrate tablets, [0m[1;31m50[0m[31m mg every [0m[1;31m6[0m[31m hours, [0m[1;31m15[0m[31m minutes after the last intravenous dose and continue for [0m[1;31m48[0m[31m hours. Thereafter, the maintenance dosage is [0m[1;31m100[0m[31m mg twice daily [0m[1;31m([0m[31msee Late [0m
[31mTreatment below[0m[1;31m)[0m[31m. Start patients who appear not to tolerate the full intravenous dose on metoprolol tartrate tablets either [0m[1;31m25[0m[31m mg or [0m[1;31m50[0m[31m mg every [0m[1;31m6[0m[31m hours [0m[1;31m([0m[31mdepending on the degree of intolerance[0m[1;31m)[0m[31m [0m[1;31m15[0m[31m [0m
[31mminutes after the last intravenous dose or as soon as their clinical condition allows. In patients with severe intolerance, discontinue metoprolol tartrate tablets [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. METOPROLOL [0m
[31mTARTRATE: dosage_and_administration: Late Treatment Start patients with contraindications to treatment during the early phase of suspected or definite myocardial infarction, patients who appear not to[0m
[31mtolerate the full early treatment, and patients in whom the physician wishes to delay therapy for any other reason on metoprolol tartrate tablets, [0m[1;31m100[0m[31m mg twice daily, as soon as their clinical [0m
[31mcondition allows. Continue therapy for at least [0m[1;31m3[0m[31m months. Although the efficacy of metoprolol beyond [0m[1;31m3[0m[31m months has not been conclusively established, data from studies with other beta-blockers suggest [0m
[31mthat treatment should be continued for [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m years. Special Populations Pediatric Patients : No pediatric studies have been performed. The safety and efficacy of metoprolol tartrate tablets in [0m
[31mpediatric patients have not been established. Renal Impairment : No dose adjustment of metoprolol tartrate tablets is required in patients with renal impairment. METOPROLOL TARTRATE: [0m
[31mdosage_and_administration: Hepatic Impairment : Metoprolol blood levels are likely to increase substantially in patients with hepatic impairment. Therefore, metoprolol tartrate tablets should be [0m
[31minitiated at low doses with cautious gradual dose titration according to clinical response. Geriatric Patients [0m[1;31m([0m[31m>[0m[1;31m65[0m[31m years[0m[1;31m)[0m[31m : In general, use a low initial starting dose in elderly patients given their[0m
[31mgreater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Method of Administration For oral treatment, the tablets should be swallowed [0m
[31mun-chewed with a glass of water. Metoprolol tartrate tablets should always be taken in standardized relation with meals. If the physician asks the patient to take metoprolol tartrate tablets either [0m
[31mbefore breakfast or with breakfast, then the patient should continue taking metoprolol with the same schedule during the course of therapy.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m


[31mCONTENT: METOPROLOL TARTRATE: pregnancy: Pregnancy Category C Upon confirming the diagnosis of pregnancy, women should immediately inform the doctor. Metoprolol has been shown to increase [0m
[31mpostimplantation loss and decrease neonatal survival in rats at doses up to [0m[1;31m11[0m[31m times the maximum daily human dose of [0m[1;31m450[0m[31m mg, when based on surface area. Distribution studies in mice confirm exposure [0m
[31mof the fetus when metoprolol is administered to the pregnant animal. These limited animal studies do not indicate direct or indirect harmful effects with respect to teratogenicity [0m[1;31m([0m[31msee Carcinogenesis,[0m
[31mMutagenesis, Impairment of Fertility [0m[1;31m)[0m[31m. There are no adequate and well-controlled studies in pregnant women. The amount of data on the use of metoprolol in pregnant women is limited. The risk to the [0m
[31mfetus/mother is unknown. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.         [0m
[31mSOURCE:METOPROLOL TARTRATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Metoprolol tartrate is indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. In a large [0m
[32mclinical study, metoprolol was shown to reduce [0m[1;32m3[0m[32m-month mortality by [0m[1;32m36[0m[32m% in patients with suspected or definite myocardial infarction. The study demonstrated that patients treated with metoprolol [0m
[32mreceived the drug both very early [0m[1;32m([0m[32mintravenously[0m[1;32m)[0m[32m and during a subsequent [0m[1;32m3[0m[32m-month period, while placebo patients received no beta-blocker treatment for this period. This indicates that metoprolol [0m
[32mtartrate decreases the risk of mortality after myocardial infarction.[0m

[32mSOURCE: METOPROLOL TARTRATE label[0m
[32mEXTRACT_START_END: Myocardial Infarction In a large [0m[32m...[0m[32m reduce [0m[1;32m3[0m[32m-month mortality by [0m[1;32m36[0m[32m%.[0m
*[1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Metoprolol tartrate is indicated[0m
[34min the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. In a large clinical study, metoprolol was shown to reduce[0m
[1;34m3[0m[34m-month mortality by [0m[1;34m36[0m[34m% in patients with suspected or definite myocardial infarction. The study demonstrated that patients treated with metoprolol received the drug both very early [0m[1;34m([0m[34mintravenously[0m[1;34m)[0m[34m [0m
[34mand during a subsequent [0m[1;34m3[0m[34m-month period, while placebo patients received no beta-blocker treatment for this period. This indicates that metoprolol tartrate decreases the risk of mortality after [0m
[34mmyocardial infarction.[0m

[34mSOURCE: METOPROLOL TARTRATE label[0m
[34mEXTRACT_START_END: Myocardial Infarction In a large [0m[34m...[0m[34m reduce [0m[1;34m3[0m[34m-month mortality by [0m[1;34m36[0m[34m%.[0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does METOPROLOL TARTRATE increase or decrease the risk of mortality after myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of mortality after myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded by indicating that METOPROLOL TARTRATE is used in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce [0m
[32mcardiovascular mortality."[0m[32m,[0m
[32m      [0m[32m"FDAHandler cited a large clinical study where metoprolol reduced 3-month mortality by 36% in patients with suspected or definite myocardial infarction. The study involved early and subsequent [0m
[32mtreatment with metoprolol compared to no beta-blocker treatment in the placebo group."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does METOPROLOL TARTRATE increase or decrease the risk of mortality after myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded by indicating that METOPROLOL TARTRATE is used in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce [0m
[34mcardiovascular mortality."[0m[34m,[0m
[34m      [0m[34m"FDAHandler cited a large clinical study where metoprolol reduced 3-month mortality by 36% in patients with suspected or definite myocardial infarction. The study involved early and subsequent [0m
[34mtreatment with metoprolol compared to no beta-blocker treatment in the placebo group."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does METOPROLOL TARTRATE increase or decrease the risk of mortality after myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether METOPROLOL TARTRATE increases or decreases the risk of mortality after myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded by indicating that METOPROLOL TARTRATE is used in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce [0m
[31mcardiovascular mortality.[0m
[1;31m3[0m[31m. FDAHandler cited a large clinical study where metoprolol reduced [0m[1;31m3[0m[31m-month mortality by [0m[1;31m36[0m[31m% in patients with suspected or definite myocardial infarction. The study involved early and subsequent [0m
[31mtreatment with metoprolol compared to no beta-blocker treatment in the placebo group.[0m
[31m        -----[0m
[31m        Final answer: METOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback [0m
[31mwas provided.[0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-mortality after myocardial infarction-METOPROLOL TARTRATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mMETOPROLOL TARTRATE decreases the risk of mortality after myocardial infarction. This conclusion is based on a large clinical study cited by the FDA, which showed that metoprolol reduced [0m[1;32m3[0m[32m-month [0m
[32mmortality by [0m[1;32m36[0m[32m% in patients with suspected or definite myocardial infarction. Patients in the study received metoprolol both very early [0m[1;32m([0m[32mintravenously[0m[1;32m)[0m[32m and during a subsequent [0m[1;32m3[0m[32m-month period, while [0m
[32mthe placebo group did not receive any beta-blocker treatment during this time.[0m
